医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Research and Markets: Epidemiology: Inflammatory Bowel Disease – Early diagnosis and improved survival lead to increased patient populations

2012年09月26日 AM02:17
このエントリーをはてなブックマークに追加


 

DUBLIN

Research and Markets (http://www.researchandmarkets.com/research/kmdx39/epidemiology) has announced the addition of the “Epidemiology: Inflammatory Bowel Disease – Early diagnosis and improved survival lead to increased patient populations” report to their offering.

Inflammatory bowel diseases (IBDs) are mainly composed of three chronic diseases; Crohn’s disease, ulcerative colitis, and indeterminate colitis. Although the etiology of inflammatory bowel disease is largely unknown, the incidence of IBD has substantially increased in the past decade.

Gain insight into market potential, including a robust 10-year epidemiology forecast of Crohn’s disease and ulcerative colitis prevalent cases.Gain insights into the current and future prevalent trends of Crohn’s disease and ulcerative colitis in the next 10 years.Understand the key epidemiologic risk factors associated with inflammatory bowel diseases.Since the 1950s, the overall incidence of IBD has gradually increased, although the increase in the incidence of ulcerative colitis (UC) precedes the increase in Crohn’s disease (CD) by approximately 15-20 years.

Across the seven major markets, Datamonitor estimates that in 2011 there were approximately 913,000 and 1.7 million prevalent cases of Crohn’s disease and ulcerative colitis, respectively.Between 2011 and 2021, Datamonitor estimates that prevalent cases of both Crohn’s disease and ulcerative colitis will increase.How will the IBD patient population change over the next decade in the seven major markets?What are the estimated prevalent cases of Crohn’s disease and ulcerative colitis in the seven major markets?

Key Topics Covered:

– OVERVIEW

– EXECUTIVE SUMMARY

– DISEASE DEFINITION AND DIAGNOSIS CRITERIA

– GLOBAL VARIATION AND HISTORICAL TRENDS

– RISK FACTORS

– EPIDEMIOLOGIC FORECASTING OF INFLAMMATORY BOWEL DISEASE

– EPIDEMIOLOGIC RESULTS

– DISCUSSION

– BIBLIOGRAPHY

– TABLES

FIGURES

Companies Mentioned

– Bull

– Hutchison 3G UK Limited

– Metro AG

– Schindler Holding Ltd.

For more information visit http://www.researchandmarkets.com/research/kmdx39/epidemiology

CONTACT

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田薬品がALK陽性非小細胞肺がんでのALUNBRIGTM(ブリガチニブ)のピボタル第2相ALTA試験の最新データを発表
  • Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″
  • Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
  • Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan
  • 武田呈报ALUNBRIGTM (brigatinib)治疗ALK阳性非小细胞肺癌枢纽性2期ALTA试验的更新结果